More and more people in the United States are living with respiratory diseases, both acute and chronic. We know that, for millions, breathing has gone from being the most natural thing in the world to being a day-to-day challenge. Putting patients first as Sunovion does, we're aware that the need for better treatments is both real and immediate, which is why we chose to specialize in this important treatment area.
Our experience with respiratory treatments dates back to our origins in Sepracor. In 1999 Sepracor launched the first product in its portfolio developed and marketed by the company itself. XOPENEX® (levalbuterol HCl) Inhalation solution, was also the first of our medications for patients with respiratory diseases. We now have five medicines approved by the Food and Drug Administration (FDA) for conditions ranging from allergies to asthma to Chronic Obstructive Pulmonary Disease (COPD), as well as more prospective medicines in our pipeline.
No one should live with breathing difficulties if there are options. And we at Sunovion can't stop looking for options while there are so many people, from the very young to the very old, who have difficulty breathing.
We have new and innovative medications and prospective medications in various stages of development, from new drug therapies completing clinical trials and awaiting FDA approval to promising new molecular compounds still in the discovery phase. Together they reflect our enduring commitment to exploring what patients need, and putting those needs first—throughout our past and present, as well as our plans for the future.